Skip Navigation

Brivaracetam Film Coated Tablets added to Adalvo Portfolio

13 September 2022

Adalvo is pleased to announce the addition of Brivaracetam film coated tablets, to our product Portfolio. We are currently working on dossier completion for this product, which is expected in September 2023 and our DCP submission is scheduled for January 2024.

Our product is being developed in collaboration with one of our strategic partners, based on the reference brand Briviact. The product is indicated as an adjunctive therapy in the treatment of partial onset seizures. The brand sold approximately $514 mio globally in 2021, having a significant growth potential with Global 3Y CAGR at 22%, according to IQVIA.

With our clearly defined product pathway, we believe we can achieve day-1 launch in all major markets.

Adalvo is working on several interesting CNS projects, as depicted below. This highlights our ability to offer differentiated, value-added products to our partners. We will continue to expand our offerings within this domain, continuously.

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.